While these inhibitors are broadly active in preclinical cancer models [3, 4] concern as to whether the lack of selectivity may adversely impact the therapeutic index has led to follow up efforts to develop isoform-selective PI3K inhibitors. This evidence concerns the gene PIK3CA and cancer.